Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338998 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
A Phase 2 study of Hemorrhagic Stroke and Intracerebral Hemorrhage (ICH), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 11
- Study locations
NCT03338998 is a Phase 2 study of Hemorrhagic Stroke and Intracerebral Hemorrhage (ICH) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 32 participants, below the 10,393-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (100% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT03338998, a Phase 2 study of Hemorrhagic Stroke and Intracerebral Hemorrhage (ICH), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
Conditions Studied
Interventions
- DRUG BAF312 solution
- DRUG Matching Placebo for BAF312 solution
- DRUG BAF312 tablet
- DRUG Matching Placebo for BAF312 tablet
Study Locations (11)
Texas
- Novartis Investigative Site - Houston
- Novartis Investigative Site - Houston
California
- Novartis Investigative Site - Palo Alto
Connecticut
- Novartis Investigative Site - New Haven
Georgia
- Novartis Investigative Site - Atlanta
Maryland
- Novartis Investigative Site - Baltimore
Michigan
- Novartis Investigative Site - Detroit
Ohio
- Novartis Investigative Site - Cincinnati
Oregon
- Novartis Investigative Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-12-24 |
| Est. Completion | 2020-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03338998
The ClinicalTrials.gov registry entry for NCT03338998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 10,393-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hemorrhagic Stroke appearing as the primary indexed condition, and to 4 interventions - of which BAF312 solution is the first listed.
NCT03338998 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03338998 about?
NCT03338998 is a clinical study titled "Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).". This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
What is the current status of trial NCT03338998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2017-12-24. Estimated completion is 2020-05-13.
What conditions does trial NCT03338998 study?
This clinical trial studies the following conditions: Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH).
What interventions are being tested in trial NCT03338998?
The interventions under investigation include: BAF312 solution (DRUG), Matching Placebo for BAF312 solution (DRUG), BAF312 tablet (DRUG), Matching Placebo for BAF312 tablet (DRUG).
Who is sponsoring clinical trial NCT03338998?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03338998 being conducted?
This trial has 11 study locations across California, Connecticut, Georgia, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhagic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Left Atrial Strain and Cryptogenic Stroke
RECRUITING
-
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
RECRUITING · NA
-
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
RECRUITING · NA
-
Stroke Recovery Initiative - Registry for Stroke Research Studies
RECRUITING
-
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
RECRUITING
-
Wireless Nerve Stimulation Device To Enhance Recovery After Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.